AtriCure updated 2026 revenue guidance to $606 to $610 million. BoxX is expected to be fully enrolled by the end of this year, with 30-day post-op AFib data planned for May of next year.
ATRC · AtriCure, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Atricure targets double-digit revenue growth and adjusted EBITDA margin north of 20 percent while eyeing a 10 billion plus market and pursuing organic R&D.
AtriCure reported third-quarter revenue of $154,450 thousand, up 15.0%, and net income of $4,064 thousand versus a $267 thousand loss. In October 2026, FDA cleared the 30 mm AtriClip FLEX-Mini device.
AtriCure reported third-quarter revenue of $154.5 million, up 15%, and raised 2026 adjusted EBITDA guidance to approximately $91 million to $94 million while expecting revenue of approximately $606 million to $610 million.
AtriCure reported third-quarter 2026 worldwide revenue of $154.5 million, up 15.0%, net income of $4.1 million and adjusted EBITDA of $26.8 million. Full-year 2026 revenue guidance is approximately $606 million to $610 million.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 3, 2026TL;DR. AtriCure delivered 15.0% worldwide revenue growth, expanded profitability and gross margin, raised adjusted EBITDA guidance, and remained on track for BOXX-NoAF enrollment and a spring 2027 readout. Risks included declining minimally invasive ablation sales, hybrid-ablation and international headwinds, expected fourth-quarter gross-margin pressure, higher clinical R&D investment, and present and potential competition in appendage management.
- + Third-quarter worldwide revenue grew 15.0% year over year to $154.5 million.
- + Third-quarter profitability expanded, with net income of $4.1 million and adjusted EBITDA of $26.8 million.
- + Third-quarter gross margin increased 180 basis points to 77.3%.
- + Management raised its 2026 adjusted EBITDA outlook to approximately $91 million to $94 million.
- + The BOXX-NoAF trial remained on track to complete enrollment before year-end, with primary-endpoint data expected in spring 2027.
- + Growth was broad-based across pain management, open ablation, and appendage management.
- − Minimally invasive ablation sales declined as hybrid procedures fell and physicians adopted PFA catheters.
- − Management identified the U.S. hybrid ablation business and international markets as continuing headwinds, with no significant international recovery expected for the rest of 2026.
- − Gross margin is expected to decline somewhat in the fourth quarter because of a full quarter of costs from the new manufacturing facility.
- − Research and development expenses increased 20.6%, excluding the PFA milestone payment, reflecting substantial clinical investment from the BOXX NO-AF trial and incremental investment in new product development.
- − Appendage management faces one competitor in the market, with potentially another competitor in the future.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Appendage management revenue | $51.61M | Three Months Ended June 30, 2026 filing | — |
| Minimally invasive ablation revenue | $6.03M | Three Months Ended June 30, 2026 filing | — |
| Open ablation revenue | $40.89M | Three Months Ended June 30, 2026 filing | — |
| Pain management revenue | $27.06M | Three Months Ended June 30, 2026 filing | — |
| Total International revenue | $28.02M | Three Months Ended June 30, 2026 filing | — |
| Total United States revenue | $125.59M | Three Months Ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ATRC
this stock
AtriCure, Inc.
|
$2.82B | +39.8% | +15.4% | 184.4 | 9.6% |
|
ISRG
Intuitive Surgical Inc
|
$151.74B | -22.7% | +20.5% | 53.1 | 2.0% |
|
BDX
Becton Dickinson & Co
|
$58.96B | — | +8.2% | 95.8 | 3.0% |
|
MDLN
Medline Inc.
|
$51.52B | -6.7% | +11.5% | — | 2.9% |
|
ALC
Alcon Inc
|
$35.38B | -6.6% | +10.5% | — | 3.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 11, 2026
- This year
- 19
AtriCure updated 2026 revenue guidance to $606 to $610 million. BoxX is expected to be fully enrolled by the end of this year, with 30-day post-op AFib data planned for May of next year.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ATRC | -4.3% | -0.4% | +101.5% | -9.7% | +39.8% |
| SPY | -1.7% | -3.5% | -1.4% | -2.1% | +8.5% |
| vs SPY | -2.6% | +3.1% | +102.9% | -7.6% | +31.3% |